Milestones to your success

OUR MILESTONES | ACHIEVEMENTS

SCOPE International has contributed to the success of many individual projects. We are particularly proud when this teamwork with our Sponsors leads to achieving product registration – the ultimate goal of clinical development.

Over the years, we have conducted a number of pivotal studies in asthma, epilepsy, pain, and pneumology resulting in European marketing authorizations:

2024

Contraceptive pill – Marketing authorization planned in the US

2023

Contraceptive pill – Marketing authorization approved in EU

2020

Contraceptive pill – Marketing authorization approved in EU

2019

Contraceptive pill – Marketing authorization approved in the US

2019

Marketing authorization granted for a contraceptive pill in the US

2017

Marketing authorization granted for an anticonvulsant for paediatric indication in the US (epilepsy)

2016

Marketing authorization granted for a COMT inhibitor in Europe (Parkinson)

2013

Marketing authorization granted for an anticonvulsant in the US (epilepsy)

Marketing authorization granted for an innovative new inhalation device for patients with asthma and/or chronic obstructive pulmonary disease (COPD) in Europe

2011

Marketing authorization granted for an opioid in the US (moderate to severe pain)

2010

Marketing authorization granted for an opioid in Europe (moderate to severe pain relief)

2009

Marketing authorization granted for an anticonvulsant (epilepsy) in Europe

2004

Marketing authorization granted for an anticonvulsant (epilepsy) in Europe

2002

Marketing authorization granted for an anti-infective drug (pneumology) in Europe